Prosecution Insights
Last updated: April 19, 2026
Application No. 18/121,311

CAVITY-SEPARATED MULTI-NANOPORE DEVICE AND METHOD PROVIDING PROTEIN SEQUENCING

Non-Final OA §102§103
Filed
Mar 14, 2023
Examiner
SINES, BRIAN J
Art Unit
1796
Tech Center
1700 — Chemical & Materials Engineering
Assignee
The Trustees of Columbia University in the City of New York
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
2y 9m
To Grant
85%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
767 granted / 954 resolved
+15.4% vs TC avg
Minimal +5% lift
Without
With
+4.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 9m
Avg Prosecution
37 currently pending
Career history
991
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
37.2%
-2.8% vs TC avg
§102
34.6%
-5.4% vs TC avg
§112
22.7%
-17.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 954 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election without traverse of group I comprising claims 1 – 14 in the reply filed on 1/20/2026 is acknowledged. Claims 15 – 18 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 1/20/2026. Drawings The drawings are objected to under 37 CFR 1.83(a). The drawings must show every feature of the invention specified in the claims. Therefore, the each of the recited features of the claimed system must be shown or the feature(s) canceled from the claim(s). No new matter should be entered. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claim 6 is objected to because of the following informalities: Claim 6 should read “a single protease nanopore” for a single nanopore, instead of nanopores. Appropriate correction is required. Claim 13 is objected to because of the following informalities: Claim 13 should read “a single protease nanopore” for a single nanopore, instead of nanopores. Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1 – 5 and 8 – 12 is/are rejected under 35 U.S.C. 102(a)(1)/(a)(2) as being anticipated by Rosenstein et al. (WO 2012/116161 A1; hereinafter “Rosenstein”). Regarding claim 1, Rosenstein teaches a system apparatus structure (pages 14 and 15; figures 18 and 19) comprising: a cavity (the top volume connecting the two V-shaped well structures each comprising a nanopore at their respective bottom); a plurality of nanopores (two nanopores at the bottom of each of the two V-shaped well structures) separated by the cavity; and a plurality of electrolyte reservoirs (the two V-shaped well structures each comprising a nanopore at their respective bottom, and capable of holding an electrolyte), each of the reservoirs being provided (i) on a side of a respective one of the nanopores, and (ii) within the cavity. PNG media_image1.png 427 645 media_image1.png Greyscale Regarding claim 2, Rosenstein teaches the system of claim 1, wherein at least one of the nanopores is fabricated with two-dimensional materials (e.g., a silicon nitride membrane; pages 14 – 16). Regarding claim 3, Rosenstein teaches the system of claim 1, wherein at least one of the nanopores is fabricated in a silicon nitride membrane (e.g., a silicon nitride membrane; pages 14 – 16). Regarding claim 4, Rosenstein teaches the system of claim 1, wherein the particular ones of the reservoirs provided on the sides nanopores are denoted as a cis chamber and a trans chamber, respectively (figure 19; see also figure 5A). Regarding claim 5, Rosenstein teaches the system of claim 1, further comprising a nanowell positioned at one of entrances of at least one of the nanopores (the two V-shaped well structures each comprising a nanopore at their respective bottom; figure 19). Regarding claim 8, Rosenstein teaches a complementary metal-oxide-semiconductor (CMOS) integrated circuit, comprising: a plurality of systems for detecting a molecular size and a molecular charge, at least one of the systems comprising: a cavity (the top volume connecting the two V-shaped well structures each comprising a nanopore at their respective bottom), a plurality of nanopores separated by the cavity (two nanopores at the bottom of each of the two V-shaped well structures), and a plurality of electrolyte reservoirs, each of the reservoirs being provided (i) on a side of a respective one of the nanopores, and (ii) within the cavity (the two V-shaped well structures each comprising a nanopore at their respective bottom, and capable of holding an electrolyte), wherein the systems are integrated onto a surface of the circuit (page 8); and a plurality of transimpedance amplifiers (page 2) configured to measure a conductance through the nanopores. Regarding claim 9, Rosenstein teaches the CMOS integrated circuit of claim 8, wherein at least one of the nanopores is fabricated with two-dimensional materials (e.g., a silicon nitride membrane; pages 14 – 16). Regarding claim 10, Rosenstein teaches the CMOS integrated circuit of claim 8, wherein at least one of the nanopores is fabricated in a silicon nitride membrane (e.g., a silicon nitride membrane; pages 14 – 16). Regarding claim 11, Rosenstein teaches the CMOS integrated circuit of claim 8, wherein the particular ones of the reservoirs provided on the sides nanopores are denoted as a cis chamber and a trans chamber, respectively (figure 19; see also figure 5A). Regarding claim 12, Rosenstein teaches the CMOS integrated circuit of claim 8, wherein the at least one of the systems comprises a nanowell positioned at one of entrances of at least one of the nanopores (the two V-shaped well structures each comprising a nanopore at their respective bottom; figure 19). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 6, 7, 13 and 14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Rosenstein et al. (WO 2012/116161 A1; hereinafter “Rosenstein”) in view of Guan et al. (US 2015/0259724 A1; hereinafter “Guan”). Regarding claim 6, Rosenstein does not specifically teach the system of claim 1, further comprising a single protease nanopore. However, Guan teaches a sensing apparatus comprising a single protease nanopore for sensing (e.g., paragraphs 9 – 11). The selection of a known material, which is based upon its suitability for the intended use, is within the ambit of one of ordinary skill in the art (see MPEP § 2144.07). The combination of familiar elements is likely to be obvious when it does no more than yield predictable results (see MPEP § 2143, A.). Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to provide a single protease nanopore for the disclosed apparatus. Regarding claim 7, Rosenstein does not specifically teach the system of claim 1, further comprising a plurality of proteases positioned in a well. However, Guan teaches a sensing apparatus comprising a plurality of proteases positioned in a well for sensing (e.g., paragraphs 9 – 11). The selection of a known material, which is based upon its suitability for the intended use, is within the ambit of one of ordinary skill in the art (see MPEP § 2144.07). The combination of familiar elements is likely to be obvious when it does no more than yield predictable results (see MPEP § 2143, A.). Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to provide a plurality of proteases positioned in a well for the disclosed apparatus. Regarding claim 13, Rosenstein teaches the CMOS integrated circuit of claim 8, wherein the at least one of the systems comprises a single protease nanopore. However, Guan teaches a sensing apparatus comprising a single protease nanopore for sensing (e.g., paragraphs 9 – 11). The selection of a known material, which is based upon its suitability for the intended use, is within the ambit of one of ordinary skill in the art (see MPEP § 2144.07). The combination of familiar elements is likely to be obvious when it does no more than yield predictable results (see MPEP § 2143, A.). Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to provide a single protease nanopore for the disclosed apparatus. Regarding claim 14, Rosenstein teaches the CMOS integrated circuit of claim 8, wherein the at least one of the systems comprises a plurality of proteases positioned in a well. However, Guan teaches a sensing apparatus comprising a plurality of proteases positioned in a well for sensing (e.g., paragraphs 9 – 11). The selection of a known material, which is based upon its suitability for the intended use, is within the ambit of one of ordinary skill in the art (see MPEP § 2144.07). The combination of familiar elements is likely to be obvious when it does no more than yield predictable results (see MPEP § 2143, A.). Therefore, it would have been obvious to a person of ordinary skill in the art before the effective filing date of the claimed invention to provide a plurality of proteases positioned in a well for the disclosed apparatus. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J. SINES whose telephone number is (571)272-1263. The examiner can normally be reached 9 AM-5 PM EST M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Elizabeth A Robinson can be reached at (571) 272-7129. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. BRIAN J. SINES Primary Patent Examiner Art Unit 1796 /BRIAN J. SINES/Primary Examiner, Art Unit 1796
Read full office action

Prosecution Timeline

Mar 14, 2023
Application Filed
Feb 18, 2025
Response after Non-Final Action
Jan 24, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599902
AUTOMATED MICROSCOPIC CELL ANALYSIS
2y 5m to grant Granted Apr 14, 2026
Patent 12602030
CONTROL DEVICE, CONTROL SYSTEM, CONTROL METHOD, AND COMPUTER-READABLE RECORDING MEDIUM
2y 5m to grant Granted Apr 14, 2026
Patent 12595168
Method for Manufacturing a Microfluidic Device
2y 5m to grant Granted Apr 07, 2026
Patent 12582988
ACTUATION SYSTEMS AND METHODS FOR USE WITH FLOW CELLS
2y 5m to grant Granted Mar 24, 2026
Patent 12571586
METHOD FOR OPERATING A PROCESS PLANT
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
85%
With Interview (+4.6%)
2y 9m
Median Time to Grant
Low
PTA Risk
Based on 954 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month